Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KQB168 in advanced solid malignancies
NCT06994806Phase 1Recruiting
- Sponsor
- Kumquat Biosciences
- Start
- Jun 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KQB168 in solid tumor malignancy (2 arms), sponsored by Kumquat Biosciences. Primary endpoints: Adverse Events at 36 months, Serious Adverse Events at 36 months and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
KQB168
03
Conditions
solid tumor malignancy
Beyond the preview
Go deeper on NCT06994806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06994806.